Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives

Area of Science:

• Oncology
• Molecular Biology
• Cancer Signaling

Background:

• The mechanistic target of the rapamycin (mTOR) pathway is a key regulator of cell survival and metabolism.
• Aberrant mTOR activation is implicated in various cancers, including non-small cell lung cancer (NSCLC).
• Current therapeutic strategies targeting the mTOR pathway in NSCLC have yielded unsatisfactory clinical results.

Purpose of the Study:

• To review recent findings on mTOR signaling mechanisms in NSCLC.
• To discuss the challenges and potential of therapeutic targeting of mTOR networks in NSCLC.
• To explore future perspectives for effective mTOR-targeted treatments in NSCLC.

Main Methods:

• Literature review of recent studies on mTOR signaling in NSCLC.
• Analysis of oncogenic roles of mTOR pathway components in NSCLC development.
• Evaluation of clinical trial outcomes for mTOR-targeted therapies in NSCLC.

Main Results:

• Increased mTOR pathway activation is a common oncogenic feature in NSCLC.
• mTOR dysregulation contributes to NSCLC's hallmarks: oncogenesis, apoptosis resistance, angiogenesis, and metastasis.
• Clinical efficacy of current mTOR inhibitors in NSCLC remains limited.

Conclusions:

• Understanding mTOR network intricacies is crucial for NSCLC treatment.
• Novel therapeutic strategies are needed to overcome challenges in targeting mTOR for NSCLC.
• Future research should focus on optimizing mTOR-related therapies for improved patient outcomes.